Company intelligence / Profile preview
Hemostatics Pharmaceuticals
Barcelona, Catalonia, Spainhemostatics.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
CM-352, the lead compound, has demonstrated high efficacy in preclinical models for major bleeding scenarios such as surgery, trauma, and intracerebral hemorrhage. It has shown safety with no acute toxicity observed in these studies. The company is preparing for Phase 1 clinical trials while seeking additional funding
- Therapeutic areas
- NeurologyHematology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Cima Universidad de Navarra
Beyond the preview
Go deeper on Hemostatics Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Hemostatics Pharmaceuticals.